# Emodin is a novel phosphatidylethanolamine anabolism inhibitor that reprograms lipid metabolism to overcome 5-fluorouracil resistance in colorectal cancer

## TL;DR

Emodin helps overcome resistance to 5-fluorouracil in colorectal cancer by inhibiting phosphatidylethanolamine anabolism and disrupting MAPK signaling.

## Contribution

Emodin is identified as a novel phosphatidylethanolamine anabolism inhibitor that targets PIM1 to reverse drug resistance.

## Key findings

- Emodin overcomes 5-fluorouracil resistance in colorectal cancer.
- Emodin inhibits phosphatidylethanolamine accumulation by targeting PIM1.
- Emodin restores PEBP1-RAF1 interaction to inactivate MAPK signaling.

## Abstract

Image 1

•Emodin overcomes 5-Fu resistance in colorectal cancer.•5-Fu drives PE accumulation to shift PEBP1 binding partners and activate MAPK signaling, which maintains drug resistance.•Emodin acts as a novel PE anabolism inhibitor by directly targeting PIM1.•Emodin reverses 5-Fu-induced PE accumulation to restore the PEBP1-RAF1 interaction to inactivate MAPK signaling.

Emodin overcomes 5-Fu resistance in colorectal cancer.

5-Fu drives PE accumulation to shift PEBP1 binding partners and activate MAPK signaling, which maintains drug resistance.

Emodin acts as a novel PE anabolism inhibitor by directly targeting PIM1.

Emodin reverses 5-Fu-induced PE accumulation to restore the PEBP1-RAF1 interaction to inactivate MAPK signaling.